PTGS2 and Crohn disease: The possibility of molecular fitting of eugenol with dual activity of COX-2/5-LOX, demonstrating its potential as an anti-inflammatory agent to act in the composition or synthesis of new selective drugs to fight diseases that need to inhibit inflammatory processes such as: osteoarthritis, Crohn's disease and cancer.